Corrections

Beware renal adverse effects of anti-vascular endothelial growth factor treatment

BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3982 (Published 07 June 2012) Cite this as: BMJ 2012;344:e3982

During the editing of this Letter (BMJ 2012;344:e3838, doi:10.1136/bmj.e3838) we inadvertently deleted the number of patients (50, as stated in the original rapid response) who developed renal thrombotic microangiopathy after taking vascular endothelial growth factor (VEGF) inhibitors. The fourth sentence in the second paragraph should have read: “Since 2005, we have identified 50 patients who developed renal thrombotic microangiopathy (small vessel injury) after taking VEGF inhibitors; 23 cases were related to intravenous bevacizumab and one followed intraocular administration of ranibizumab.”

Notes

Cite this as: BMJ 2012;344:e3982

View Abstract